- Sections :
- Crime & Public Safety
- Restaurants & Food
- Sports
- More
Categories
Research & Science
Power3 Medical Products, Inc. has released an interim status report of its international validation study of the company’s NuroPro® blood serum biomarker test for Parkinson’s disease.
Repros Therapeutics Inc. has initiated its Phase 2b clinical study monitoring the effects of the company's oral drug Androxal® on male fertility and testicular function in patients being treated for low testosterone.
Repros Therapeutics drug Proellex showed no gross potential for tumor induction in a recently released mouse study.
Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) has received Fast Track status from the(FDA) for development of LX1032, a drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome.
Repros Therapeutics Inc. has released encouraging results from its one-year extension safety study of Proellex in the chronic treatment of the symptoms associated with uterine fibroids.
The Interior Department ruled Wednesday that the polar bear will be protected as a threatened species.
Lexicon Pharmaceuticals, Inc. has announced that a member of its senior management will present at the Bank of America Health Care Conference on May 14.
Lexicon Pharmaceuticals has obtained positive results from its initial Phase 1 clinical trial of its orally-delivered drug candidate for the treatment of rheumatoid arthritis and other autoimmune conditions.
Lexicon Pharmaceuticals, Inc. recently presented data describing the target of it's drug for cognitive disorders, LX6171, and initial Phase 1 clinical results at the American Academy of Neurology in Chicago.
Power3 Medical Products, Inc. has received its Clinical Laboratory Improvement Amendments (CLIA) compliance recertification following a CLIA regulatory inspection.
Power3 Medical Products, Inc. was recently spotlighted in several prominent local, national, and international news outlets.
Power3 Medical Products, Inc.’s CEO, Steven Rash has contributed an article to the April 2008 issue of IVD Technology magazine.
Repros Therapeutics Inc. has announced that the safety of it’s drug Proellex® appears to be enhanced with repeated cycles of treatment followed by off drug intervals.
Lexicon Pharmaceuticals, Inc. will present at the Future Leaders in the Biotech Industry Conference in New York on March 27.
Power3 Medical Products, Inc. has commenced a 300 patient clinical validation study of its NuroPro diagnostic test for Alzheimer’s disease and Parkinson’s disease.
Power3 Medical Products, Inc. has published the discovery of protein biomarkers for esophageal malignancies in the International Journal of Cancer.
Power3 Medical Products, Inc. has filed a U.S. Utility Patent application for 47 protein biomarkers of neurodegenerative disease in human blood serum.
Power3's BC-SeraPro™ blood test for the detection of breast cancer has been introduced into several Middle Eastern countries.
Marvel at rocks that glow in the dark in the new HMNS “Glow in the Dark” Fluorescent Rock Mine, now on display at The Woodlands Xploration Station.
Early, definitive detection for Alzhiemer's disease may ultimately be as important as treatment or a final cure.
